NEWTOWN, Penn. (January 25, 2010)— Quotient Biodiagnostics, Inc., today announced that it has entered into a 3-year agreement with Carter BloodCare to become the Center’s main supplier of traditional transfusion diagnostics products. The deal will include Quotient’s first 15 monoclonal antibodies in its proprietary line of transfusion diagnostics as well as future products, as they become FDA approved and available.
Founded in 1998 by the merger of two local blood centers, Carter BloodCare has grown to become Texas' largest blood center, providing more than 330,000 units of lifesaving blood to North, Central and East Texas each year.
“We are exceptionally pleased that Carter BloodCare selected Quotient Biodiagnostics as their primary partner for manual transfusion diagnostics products after a thorough review of our product portfolio,” said Jeremy Stackawitz, President and CEO, Quotient Biodiagnostics. “They join our growing list of valued customers who are interested in purchasing high-quality, cost-effective products in combination with a superior customer service experience.”
Formed in 2009, Quotient Biodiagnostics sells its proprietary line of anti-sera products under the trade name ALBAclone®. Quotient provides innovative, high-quality and cost-effective solutions to the worldwide transfusion medicine market to help ensure safe and reliable transfusions.
Quotient Biodiagnostics’ current portfolio includes products used in forward blood typing, namely Anti-A, Anti-B, Anti-AB, Anti-D, Anti-E, and Anti-c, as well as some rare anti-sera including Anti-k, Anti-M, Anti-N, Anti- Lea, Anti-Leb, and Anti-Lub – all monoclonal antibodies. Quotient also has two specialty products in its initial portfolio including the ALBAclone® Advanced Partial RhD Typing Kit which identifies weak and partial RhD types with results comparable to molecular analysis at a fraction of the cost, and the Quant-Rho® FITC Anti-D product that quantifies Fetal Maternal Hemorrhage without the tribulations of KB staining. In addition, Quotient has several applications pending before, or soon to be submitted to, the FDA to complete its full portfolio of manual reagents of nearly 60 products.
"We selected Quotient Biodiagnostics as our transfusion diagnostics supplier after a thorough review of their product line and customer service model,” says Dawn Webber, Director of Reference and Transfusion Services. “We appreciate their commitment to excellence in providing a quality product line that meets our needs as well as the overall support system that exists after the sale.”
Those interested in learning more about Quotient Biodiagnostics and its line of products are encouraged to visit www.QuotientBD.com, or call the customer service line 888-284-1901, or e-mail customer.service@QuotientBD.com
About Quotient Biodiagnostics
Quotient Biodiagnostics is the diagnostics division of Quotient Bioscience Group (United Kingdom), and through its wholly owned subsidiary, Alba Bioscience, brings over 30 years of experience in the transfusion medicine market to the Group. Quotient will focus on providing innovative, high-quality and cost-effective solutions to the worldwide transfusion medicine market, helping to ensure safe and reliable blood transfusions. Quotient’s goal is to develop innovative new products and technologies to serve the worldwide transfusion medicine market, build a commercial operation (initially in North America) to market and sell the Group’s blood typing and screening products and continue as an important supplier of key raw materials and innovative new products to the Original Equipment Manufacturers market.
About Carter BloodCare
Carter BloodCare’s volunteer blood donors provide lifesaving blood for patients at more than 200 healthcare facilities in 56 counties in North, Central and East Texas. Carter BloodCare is a not-for-profit 501(c)(3) organization that is licensed by the Food and Drug Administration, accredited by the American Association of Blood Banks, and is a member of America’s Blood Centers.